We evaluated the impact of the number of cycles of platinum based, first line chemotherapy (fewer than 6 cycles vs the conventional 6 cycles or more) on the survival of patients with metastatic urothelial carcinoma. Materials and Methods: We used the RISC (Retrospective International Study of Invasive/Advanced Cancer of the Urothelium) database. The association of the number of cycles of chemotherapy with overall survival was investigated by Cox multiple regression analysis after controlling for recognized prognostic factors. We excluded patients who received fewer than 3 or more than 9 platinum chemotherapy cycles to reduce confounding factors. The primary analysis was a comparison of overall survival for 3 to 5 vs 6 to 9 cycles using 6-month landmark analysis when 281 death events were observed. Results: Of the 1,020 patients in the RISC 472 received cisplatin or carboplatin, of whom 338 and 134, respectively, were evaluable. A total of 157 patients received 3 to 5 cycles (median 4) and 315 received 6 to 9 cycles (median 6). There was no significant difference in overall survival between 3 to 5 and 6 to 9 cycles (HR 1.02, 95% CI 0.78e1.33, p ¼ 0.91). No significant interactions were observed for the type of platinum (p ¼ 0.09) and completed planned chemotherapy (p ¼ 0.56). The limitations of a hypothesis generating, retrospective analysis applied.
Purpose:
We evaluated the impact of the number of cycles of platinum based, first line chemotherapy (fewer than 6 cycles vs the conventional 6 cycles or more) on the survival of patients with metastatic urothelial carcinoma. Materials and Methods: We used the RISC (Retrospective International Study of Invasive/Advanced Cancer of the Urothelium) database. The association of the number of cycles of chemotherapy with overall survival was investigated by Cox multiple regression analysis after controlling for recognized prognostic factors. We excluded patients who received fewer than 3 or more than 9 platinum chemotherapy cycles to reduce confounding factors. The primary analysis was a comparison of overall survival for 3 to 5 vs 6 to 9 cycles using 6-month landmark analysis when 281 death events were observed. Results: Of the 1,020 patients in the RISC 472 received cisplatin or carboplatin, of whom 338 and 134, respectively, were evaluable. A total of 157 patients received 3 to 5 cycles (median 4) and 315 received 6 to 9 cycles (median 6). There was no significant difference in overall survival between 3 to 5 and 6 to 9 cycles (HR 1.02, 95% CI 0.78e1.33, p ¼ 0.91). No significant interactions were observed for the type of platinum (p ¼ 0.09) and completed planned chemotherapy (p ¼ 0.56). The limitations of a hypothesis generating, retrospective analysis applied.
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Supported in part by National Cancer Institute Cancer Center Support Grant P30 CA008748. Nevertheless, patients who receive first line therapy with PD-1/PD-L1 inhibitors may still undergo subsequent platinum based chemotherapy.
However, cisplatin in particular is associated with significant cumulative toxicities, especially neuropathy, venous thromboembolism and renal dysfunction, which may be irreversible and sometimes lethal, rendering it challenging to deliver the full course of 6 cycles of treatment. 9, 10 While carboplatin based chemotherapy has a more favorable toxicity profile, myelosuppression may lead to infectious complications, thrombocytopenic bleeding and anemia, which may require transfusions. Given that the UC population is frequently elderly and frail, a reduction in the number of cycles may confer a more optimal therapeutic index and should be considered if anticancer efficacy is not appreciably compromised. Moreover, the choice of 6 cycles of therapy is arbitrary and not based on prospective comparison with a different number of targeted cycles of therapy.
Furthermore, an explosion of new possibilities of active systemic therapies for patients in whom standard first line chemotherapy fails has characterized the last few years. Several clinical trials as well as the use of immune checkpoint inhibitors as the standard of care in the second line setting may now be offered to patients, provided that patient performance status permits. Consequently refining sequencing strategies for patients with advanced UC requires special focus on the number of cycles of chemotherapy that should be offered.
Since to our knowledge this issue has not been investigated prospectively, we performed a retrospective analysis.
PATIENTS AND METHODS

Study Population
We used the RISC database to perform a retrospective analysis. The RISC is a retrospective study encompassing individual patient level data on patients with muscle invasive or advanced UC, or nonUC histology who received systemic therapy during the disease course. This contemporary database includes data gathered from hospitals in the United States, Europe, Israel and Canada on patients treated between 2006 and 2011. The RISC study was approved by the ethics committee at each participating institution.
In July 2017 we extracted data on select patients with the same characteristics as those in a previously published analysis, including a predominant UC histology, cisplatin or carboplatin containing combination chemotherapy administered in the first line metastatic setting and availability of the number of cycles administered. 11 The study was approved by the regulatory committees at each participating institution.
Statistical Analyses
The study objective was to analyze the association between the total number of cycles of platinum based combination chemotherapy administered and the patient outcome. OS was the primary end point. This association was investigated by Cox multiple regression analysis controlling for the platinum agent (cisplatin or carboplatin) and for the previously recognized, baseline prognostic factors reported in the RISC nomogram, ie the ECOG-PS, white blood count, BMI, ethnicity, lung, liver or bone metastases and prior perioperative chemotherapy. 11 We excluded patients who received fewer than 3 or more than 9 cycles of first line platinum based chemotherapy to reduce confounding due to early removal for toxicity, early progression or patient decision and an increased number of cycles due to response and patient related factors.
The primary analysis was a comparison of 3 to 5 cycles vs 6 to 9 cycles. Supportive subanalyses were performed to compare 3 to 5 vs 6 vs 7 to 9 cycles and exactly 4 vs exactly 6 cycles, platinum type (cisplatin or carboplatin) and patients who completed planned chemotherapy according to investigator reports. Additionally, sensitivity analyses were run, excluding patients who had disease progression as the best response to treatment. Sixmonth landmark analysis was applied throughout, accounting for OS events. Statistical analyses were done with SASÒ, version 9.4 and R, version 3.4.2 (https://www.r-project.org/foundation/) with statistical significance considered at the conventional 2-sided 5% threshold.
RESULTS
Patient Characteristics
Of the 1,020 available patients with metastatic UC in the RISC nomogram database 52 were excluded from study due to the receipt of fewer than 3 or more than 9 chemotherapy cycles and 496 were excluded because they did not fulfill the landmark criterion. Thus, 472 patients were evaluable for the landmark analysis, including 338 and 134 who received cisplatin and carboplatin, respectively, with a total of 281 events (supplementary table, http://jurology. com/, and fig. 1 ).
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The primary tumor site was the bladder in 381 patients, the upper tract in 87 and an unknown site in 4. When examining by world region, 337 patients were from Europe, 129 were from the United States and 6 were from Israel. As estimated by the reverse Kaplan-Meier method median followup in the evaluable population was 35.8 months (IQR 23.1e55.8). A total of 157 patients received 3 to 5 cycles (median 4) and 315 received 6 to 9 cycles (median 6). Median OS in the evaluable population was 21.8 months, and age and gender characteristics were typical in this population (supplementary table, http://jurology.com/).
When comparing the groups that received 3 to 5 vs 6 to 9 cycles, there was no statistically significant difference in platinum type, the ECOG-PS, leukocytosis, BMI or ethnicity. However, visceral metastases were a more frequent factor in the 6 to 9 cycle group and prior perioperative chemotherapy was more common in the 3 to 5 cycle group.
Cox Model Analysis of Association of Number of Platinum Cycles and Survival
There was no significant difference between 3 to 5 and 6 to 9 cycles of platinum based chemotherapy (HR 1.02, 95% CI 0.78e1.33, p ¼ 0.91, see table and fig. 2, A) . Similarly there was no significant difference between exactly 4 and 6 cycles (HR 0.89, 95% CI 0.60e1.33, p ¼ 0.57, fig. 2 , B) or between 3 to 5 vs 6 vs 7 to 9 cycles (overall p ¼ 0.877, see table) .
No significant interactions were observed of platinum type ( fig. 2 , C, p ¼ 0.09) with the completed planned chemotherapy indication (p ¼ 0.56). Similar findings were obtained after excluding patients with progressive disease as the best response to platinum based chemotherapy and those who were not excluded by landmark analysis for a total of 448 select patients (6 to 9 vs 3 to 5 N=1,020 who received first-line platinum-based chemotherapy No differential association was observed of survival with 3 to 5 vs 6 to 9 cycles when examining by the prognostic risk group tertiles defined in the RISC nomogram ( fig. 3 ).
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DISCUSSION
While advanced UC trials have targeted the delivery of 6 cycles of platinum based chemotherapy, this was based on arbitrary decisions. To our knowledge randomized trials have not been designed to inform the optimal number of cycles.
In recent meta-analyses of trials on cisplatin eligible or ineligible patients the median number of cycles administered in each study was 4 (range 3 to 6) in cisplatin-gemcitabine studies; 4.5 (range 4 to 6) in taxane, cisplatin and gemcitabine studies; 5.5 (range 4 to 7) in gemcitabine-taxane studies; and 4 (range 3 to 6) in gemcitabine-carboplatin studies. 12, 13 Moreover, platinum based combination chemotherapy is characterized by multiple toxicities and decreased performance status, which may undermine the ability to perform second line therapy and negatively impact quality of life and survival.
Additionally, given the ongoing clinical investigations of second line, switch maintenance therapy with PD-1 or PD-L1 inhibitors in patients with stable but responding disease after first line therapy, the feasibility of this approach will be optimized if patients are not burdened by residual toxicity from first line therapy. Indeed, ongoing second line, switch maintenance trials have required at least 4 and not 6 cycles of prior platinum based chemotherapy, including the JAVELIN Bladder 100 (Study of Avelumab in Patients with Locally Advanced or Metastatic Urothelial Cancer (ClinicalTrials.gov NCT02603432) and Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy after Initial Chemotherapy in Metastatic Bladder Cancer (ClinicalTrials.gov NCT02500121). Moreover, given the potential addition of other new agents (eg enfortumab vedotin) and combinations (eg docetaxel plus ramucirumab) to the post-platinum therapeutic armamentarium, the absence of lingering overlapping toxicities of first line platinum based chemotherapy, especially neuropathy, would facilitate the delivery of a larger number of lines of agents sequentially. 14, 15 In this context it is notable that the optimal duration of PD-1 and PD-L1 inhibitors in the first line cisplatin ineligible and post-platinum settings also remains unresolved and should be examined. 6,7,16e21 It is reasonable to hypothesize that optimizing the duration of PD-1 and PD-L1 inhibitors would facilitate the delivery of subsequent third line therapy. This retrospective analysis of the large, individual patient level RISC database with an excellent followup of a median of 35.8 months demonstrates that 3 to 5 cycles of platinum based, first line combination chemotherapy may be adequate to treat advanced UC. Patients who are removed early from therapy with fewer than 3 cycles due to toxicity, progression or other reasons were excluded from analysis to avoid confounding. This led to a relatively chemosensitive population for analysis, as reflected by the somewhat favorable median survival of approximately 22 months in the entire cohort.
Clinical characteristics of the patients were quite balanced in the groups with less than 6 vs 6 or more cycles with no consistently unfavorable features in any specific group (supplementary table, http:// jurology.com/). There was no significant difference in OS between patients who received 3 to 5 vs 6 to 9 cycles of platinum based first line chemotherapy (HR 1.02, p ¼ 0.91). We also observed no significant interactions with the type of platinum or with completed planned chemotherapy as defined by the treating physician.
Secondary analyses, including comparison of exactly 4 vs exactly 6 cycles and 3 to 5 vs 6 vs 7 to 9 cycles, also yielded no significant differences in the association with OS. When examining data for the impact of the number of cycles of first line, platinum based combinations across malignancies, the observed results generally did not suggest that a large number of cycles may yield significant increments. Metastatic small cell cancer and nonsmall cell lung cancer have been treated with 4 cycles since data do not support a benefit for more cycles. 22e24 In good risk cases of metastatic germ cell tumors 4 cycles of cisplatin based combination chemotherapy (bleomycin, etoposide and cisplatin) did not prove to be superior to 3 cycles. 25, 26 Although patients with intermediate or poor risk germ cell tumors continue to receive 4 cycles of bleomycin, etoposide and cisplatin, to our knowledge no data support administering more than 4 cycles and cumulative toxicity is feared. In metastatic colorectal cancer cases oxaliplatin based chemotherapy is conventionally interrupted after 3 or 4 cycles to avoid cumulative neurotoxicity while recent data also suggest that 3 months of adjuvant therapy may be adequate. 27e29 In ovarian cancer cases 6 cycles of platinum based chemotherapy are targeted by convention with no data on the need for 6 cycles. 30 One may hypothesize that patients in the good prognostic group may benefit to a greater extent when more than 6 cycles are given due to more favorable chemosensitive disease and better tolerance of adverse effects. We excluded patients who received more than 9 cycles to avoid bias generated by including such patients. This group is likely to be enriched with outlying patients with an extremely durable benefit. However, no differential association was observed in survival for 3 to 5 vs 6 to 9 cycles when examining by nomogram defined risk group tertiles. We excluded patients who received fewer than 3 cycles for any reason to reduce confounding for early removal for unaccountable reasons since removal for progressive disease, toxicity or patient decision were all possible. We also performed a supportive subanalysis after removing those with the best response of progressive disease at any time point for the few patients who remained evaluable after applying landmark analysis. This did not show a difference in 3 to 5 vs 6 to 9 cycles. While different cutoffs instead of fewer than 3 and more than 9 cycles could have been used to exclude patients, these criteria appeared reasonable, although they may have been arbitrary.
The limitations of a hypothesis generating retrospective analysis apply. We cannot exclude a benefit in a minor subset of patients who received 6 or more cycles. In this context the low prognostic risk group tertile appeared to show a separation in survival for 6 or more cycles but this did not attain statistical significance ( fig. 3, A) .
A subanalysis of patients who had at least stable disease after 6 cycles may have been complementary. However, these data were unavailable since radiographic assessments were not performed at identical periodic intervals in all patients. Also, although the best response was captured, the response category was not captured at the time of every radiographic examination.
The correlation of toxicity with the number of cycles would also be a valuable complementary analysis. Patients who tolerate the therapy better may receive more cycles and, consequently, experience better outcomes. Indeed, it is intriguing that despite this confounding factor which would bias analysis in favor of more cycles, we could not identify such an association. Conversely some toxicities are a clinical pharmacodynamic marker of therapy activity which may be associated with better outcomes. While we excluded patients removed for any reason who received fewer than 3 cycles, we did not capture toxicities beyond 3 cycles or more in this data set to analyze the association of toxicities (nephrotoxicity and neurotoxicity) with the number of cycles and with survival. 
CONCLUSIONS
EDITORIAL COMMENT
Sonpavde et al report the results of a study evaluating the optimal number of cycles of first line, platinum based chemotherapy in patients with advanced urothelial carcinoma. While trials have been done to investigate the most effective platinum based regimen, there is limited guidance regarding the optimal number of cycles of chemotherapy.
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Based on the results of these trials most patients in clinical practice are treated with the goal of completing 6 or more cycles, a number that was arbitrarily chosen in these trials. Using patient level data on 472 patients included in the highly curated RISC consortium database the authors observed similar overall survival in patients treated with 3 to 5 (median 4) and 6 to 9 (median 6) cycles of platinum based chemotherapy. The results are highly relevant to real world management of these cases. Considering the older age of this population and the accompanying comorbidities, it is crucial to weigh the benefits of palliative chemotherapy against toxicities, which can often be irreversible and can preclude these patients from receiving subsequent therapies. The results suggest that additional platinum based chemotherapy beyond 4 cycles may be omitted in select patients without compromising survival.
